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Background: Referring to individuals with reactivity to honey bee and Vespula venom in diagnostic tests, the
umbrella terms “double sensitization” or “double positivity” cover patients with true clinical double allergy and
those allergic to a single venom with asymptomatic sensitization to the other. There is no international consensus
on whether immunotherapy regimens should generally include both venoms in double sensitized patients.
Objective: We investigated the long-term outcome of single venom-based immunotherapy with regard to
potential risk factors for treatment failure and specifically compared the risk of relapse in mono sensitized and
double sensitized patients.
Methods: Re-sting data were obtained from 635 patients who had completed at least 3 years of immunotherapy
between 1988 and 2008. The adequate venom for immunotherapy was selected using an algorithm based on
clinical details and the results of diagnostic tests.
Results: Of 635 patients, 351 (55.3%) were double sensitized to both venoms. The overall re-exposure rate to
Hymenoptera stings during and after immunotherapy was 62.4%; the relapse rate was 7.1% (6.0% in mono
sensitized, 7.8% in double sensitized patients). Recurring anaphylaxis was statistically less severe than the index sting
reaction (P = 0.004). Double sensitization was not significantly related to relapsing anaphylaxis (P = 0.56), but there
was a tendency towards an increased risk of relapse in a subgroup of patients with equal reactivity to both venoms
in diagnostic tests (P = 0.15).
Conclusions: Single venom-based immunotherapy over 3 to 5 years effectively and long-lastingly protects the vast
majority of both mono sensitized and double sensitized Hymenoptera venom allergic patients. Double venom
immunotherapy is indicated in clinically double allergic patients reporting systemic reactions to stings of both
Hymenoptera and in those with equal reactivity to both venoms in diagnostic tests who have not reliably identified
the culprit stinging insect.
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Implementation of venom immunotherapy (VIT) in a
Hymenoptera venom allergic patient involves a number
of individual decisions weighing aspects of treatment
efficacy and optimal protection versus costs, feasibility,
and patient convenience. International guidelines [1-3]
provide elaborate instructions on dosing and duration of
VIT, but there is no definite statement on which venoms
to include for immunotherapy if sensitization to more
than one venom is detectable.
Sensitization to both honey bee and Vespula venom is
a common finding in up to 59% [4] of Northern
European Hymenoptera venom allergic patients. The
terms “double sensitization” or “double positivity”, how-
ever, refer to the results of diagnostic tests rather than to
their clinical significance. In the past decades, substantial
efforts have been made to differentiate between venom
“cross-reactivity” due to partial sequence identity of pro-
tein allergens or cross-reactive carbohydrate determi-
nants and “independent double sensitization” by means
of serological [4-11] or cellular tests [12-14]. Recently,
assays of species specific IgE to recombinant major
allergens such as rApi m1 and rVes v5 and lately rVes
v1 [4-6] became commercially available for diagnostic
testing. “Independent” or major allergen-based double
sensitization has been considered an indication for
double VIT [4,6,10,13], and some experts recommend
that VIT should be extended to all venoms for which
test results are positive and patients might potentially
react to [15]. Still, there is a lack of clinical studies inves-
tigating whether double sensitization – regardless of its
pattern or origin – is objectively associated with an in-
creased risk of future anaphylactic reactions to both Hy-
menoptera venoms and therefore necessitates double
VIT, entailing a significant increase of health care costs
and time and effort.
Our study retrospectively examines a large cohort of
patients who were treated by single venom-based im-
munotherapy at a standard dose of 100 μg per injection
for at least 3 years between 1988 and 2008. It was
designed to evaluate the risk of relapsing Hymenoptera-
sting induced allergic reactions during maintenance VIT
and after its discontinuation, to analyze risk factors for
treatment failure, and to specifically compare the risk of
field sting-induced anaphylaxis in mono sensitized and
double sensitized patients.
Methods
Patients
In this retrospective single centre observational cohort
study covering a period of 20 years (1988 to 2008), 721
patients were screened for study inclusion criteria.
Patients with proven honey bee or Vespula venom al-
lergy were eligible for evaluation if single venom-basedimmunotherapy had been performed according to inter-
national guidelines [1-3] and discontinued after a mini-
mum period of 3 years. Patients who had received VIT
with both venoms, those who stopped treatment before
3 years duration, and those who did not present for
follow-up visits were excluded from the study. All
patient-related procedures were part of routine diagnos-
tic practice; written informed consent was obtained for
allergologic work-up and initiation of VIT.
Collection of data
Patients fulfilling study inclusion criteria were identified
from patient files. A detailed follow-up history using a
standardized questionnaire was routinely taken on the
occasion of control visits in our allergy clinic. Data col-
lection included information on patient-specific data
(age at the time of VIT initiation, sex, underlying atopy
or asthma) and on Hymenoptera field stings before,
during and after VIT (date, number of stings, culprit
insect, symptoms and severity of anaphylaxis, self-
administration of medication, emergency treatment). Re-
sults from allergy testing (intradermal skin test results,
specific IgE, baseline serum tryptase) and information
on the course of VIT (time-interval between index-sting
and VIT initiation, date of VIT initiation and duration of
VIT) were retrieved from the patients’ files. Patients
reporting relapses after discontinuation of VIT were in-
vited for retesting and advised to restart VIT.
Grading of anaphylaxis
Severity of anaphylaxis was classified as mild, moderate
or severe with respect to cutaneous, respiratory, cardio-
vascular, gastrointestinal, and neurological symptoms
according to a modified version of the system proposed
by Muraro [16] as has been described previously [17].
Allergy testing
Intradermal and serological tests were performed before
initiation and prior to cessation of VIT. Intradermal skin
tests with 10-fold serial dilutions of honey bee and
Vespula venom (ALK-Abelló, Wedel, Germany) were
carried out according to international guidelines [18,19].
Intradermal skin test responses at endpoint concentra-
tions of less than or equal to 1.0 μg/mL were considered
“positive” when resulting in a minimum wheal of 5 mm.
Venom-specific IgE levels were determined using an
enzyme immunoassay technique (DPC Biermann, Bad
Nauheim, Germany) before 1998, which was replaced by
the ImmunoCAP™ method (Thermo Fisher Scientific,
Schwerte, Germany). The results were categorized by
semi-quantitative classes ranging from 0 to 6. Classes
higher than or equal to 1 were considered “positive”.
Additional diagnostic methods including determination
of specific IgE to recombinant major venom allergens
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Figure 1 Algorithm for the selection of venom for
immunotherapy. A. Reliable visual identification of the culprit
stinging insect or sufficiently certain identification based on
additional sting-related information (patient’s location and activity,
time of the year, presence of a stinger left in the skin): administer
single VIT. B. Culprit insect not identified: administer single VIT in
mono sensitized patients or if sensitization to a single venom is
significantly stronger than to the other (i.e. at least one serological
class and one concentration step in intradermal tests). Administer
double VIT in patients with equal reactivity to both venoms. C.
Patients reporting anaphylaxis to stings of both insects: administer
single VIT in mono sensitized patients. Administer double VIT in all
patients with double sensitization.* Consider double VIT if additional
risk factors are present (e.g. comorbidities, severe anaphylaxis to
index sting, high degree of exposure). Dashed boxes: patients
receiving double VIT were not eligible for study inclusion.
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termination of the baseline serum tryptase was introduced
in routine diagnostic practice in 2002 and was performed
using ImmunoCAP Tryptase™ (Thermo Fisher Scientific)
in a subgroup of patients with a history of severe sting-
induced anaphylaxis. Tryptase levels exceeding 11.4 μg/L
(95th percentile of the general population) were consid-
ered as elevated.
Choice of venom for VIT
The venom for immunotherapy was selected based on a
detailed clinical history and the results of skin and sero-
logical tests, taking into account the respective degree of
reactivity to both venoms (Figure 1).
VIT venoms and protocols
VIT was administered according to international guide-
lines [1-3] using standardized allergen extracts containing
Vespula or honey bee venom. Reless™ (ALK-Abelló,
Wedel, Germany) was used from 1988 to 1999, and ALK-
lyophilisiert SQ™ and ALK-depot SQ™ (ALK-Abelló,
Wedel, Germany) were used for build-up and mainten-
ance phase since 2000. Before 2007, initiation of VIT was
performed using a 5-day rush protocol which was subse-
quently replaced by a 3-day rush protocol. The mainten-
ance dose of 100 μg was administered every 4 to 8 weeks
according to the manufacturer’s instructions. Treatment
was discontinued within 3 to 5 years in the majority of
cases (96.5%); 22 patients (3.5%) pursued extended VIT
for individual reasons.
Definition of patient groups for statistical analysis
Patients were defined as “double sensitized” in the case
of a positive intradermal skin test response and/or sero-
logical detection of specific IgE to both, honey bee and
Vespula venom. A subgroup of 116 individuals com-
prised patients with equal reactivity to both venoms in
diagnostic tests as well as a small number of patients
(n=14) with discrepant diagnostic results (i.e. skin test
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the other venom).
Statistical analysis
Results are presented as numbers and frequencies for
categorially scaled measures or as median and range for
metrically scaled data. In case of metric data, the Wilcoxon
signed-rank test was performed for the comparison of two
dependent measures and the Mann–Whitney test for
unpaired samples. To assess the relationship between two
independent categorial measures, the chi-square test or the
exact test of Fisher were used as appropriate. In case of
dependent categorial data the Bower test was conducted.
The binomial test was done for the comparison of two pro-
portions. All tests were two-tailed and differences were
considered statistically significant if P < 0.05. The software
package used was IBM SPSS for Windows, version 19.0.
Results
Clinical data
The files of 721 patients with proven honey bee or
Vespula venom allergy who had received VIT between
1988 and 2008 were screened for study inclusion criteria.
Of 679 individuals who had completed at least 3 years of
VIT, 14 patients who had received VIT with both venoms
were excluded from evaluation. 30 patients were lost to
follow-up, e.g. due to change of residence or death from
causes unrelated to Hymenoptera venom allergy. Thus,
complete data of 635 patients who had received single
venom-based immunotherapy were available for evaluation
as summarized in Table 1. The median age at the time of
VIT initiation was 39 years (ranging from 5 to 77). The sexTable 1 Clinical data of the cohort
n %*
Number of patients 635
Median age at time of VIT-initiation (years) (range) 39 (5–77)
Male/female 322/313
Results of allergy testing
Vespula (vulgaris/germanica) mono sensitization 251 39.5
Honey bee (Apis mellifera) mono sensitization 33 5.2
Double sensitization 351 55.3
Severity of anaphylaxis to pre-VIT index field sting
Large local reaction 8 1.3
Grade I (mild) 171 26.9
Grade II (moderate) 321 50.6
Grade III (severe) 135 21.3
Treatment course
Mean duration of VIT (years) (range) 3.9 (3–13)
Mean observation time after VIT (years) (range) 7.0 (0–17)
* Percentages refer to the total study group of 635 patients.ratio was almost balanced with only a slight male predom-
inance (50.7%). Of 635 venom allergic patients, 351
(55.3%) were double sensitized to honey bee and Vespula
venom as detected by intradermal tests or serum specific
IgE. The majority of double sensitive cases (n=160) were
detected by both, serologic and intradermal tests (Table 2).
107 patients were double positive only serologically, and 84
only in skin tests. Double sensitization was more prevalent
in individuals with honey bee venom allergy compared to
those who had reacted to Vespula stings (77.9% versus
48.4%, P < 0.001). 135 (21.3%) patients had a history of se-
vere (grade III) reactions following pre-VIT Hymenoptera
field stings, 321 (50.6%) index sting reactions were moder-
ate (grade II), and 171 (26.9%) were classified as mild
(grade I). In 8 venom-sensitized patients (1.3%) with a his-
tory of large local sting reactions, VIT had been performed
for individual reasons (mainly loss of quality of life due to
fear of Hymenoptera stings). The mean duration of VIT
was 3.9 years (ranging from 3 to 13) years. In the whole
study population, no major side effects of VIT injections
were reported. The mean observation time following dis-
continuation of VIT was 7.0 years (ranging from 1 month
to 17 years).
Skin test and serological reactivity before and by the end
of VIT
Skin test reactivity and specific IgE significantly de-
creased during VIT (P < 0.001). By the end of treatment,
intradermal tests with the venom used for immunother-
apy were negative in 67 (10.6%) patients, and serum
venom-specific IgE was negative (< 0.35 kU/L) in 128
(20.2%) patients.
Risk of relapse and risk of severe reactions during and
after VIT
396 of 635 patients reported at least one Hymenoptera
sting after initiation of VIT by either honey bee (n = 74),
Vespula (n = 233), European hornet (n = 2), bumble bee
(n = 1) or by an unidentified stinging insect (n = 86),
resulting in a re-sting rate of 62.4%. 174 (27.4%) patients
got stung on several occasions: 98 (15.4%) patients had 2
stings, 34 (5.4%) patients had 3 stings, 20 (3.1%) had 4
stings, 8 (1.3%) had 5 stings, and 14 (2.2%) had more
than 5 stings – several stings on the same event were
counted as one sting. In case of repeated stings, detailsTable 2 Mono sensitization and double sensitization
detected by intradermal tests and serum specific IgE
Serum specifc IgE
Mono
sensitization
Double
sensitization
Skin test Mono sensitization 284 107
Double sensitization 84 160
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most recent field sting were documented: the outcome
of 396 field stings (230 of which occurred in double
sensitized patients) is summarized in Table 3. 150 field
stings took place during VIT, 246 occurred after stop-
ping treatment. Of 396 patients re-stung, 28 reported
systemic reactions, implying an overall relapse rate of
7.1%. During VIT, systemic reactions occurred in 5
stings, and no severe reactions were reported. After dis-
continuation of VIT, 23 stings led to systemic reactions,
2 of which were classified as severe. Recurring anaphyl-
actic reactions were found to be significantly less severe
than the pre-VIT index sting reaction (P = 0.004). Char-
acteristics of the 28 patients who suffered systemic ana-
phylaxis following Hymenoptera field stings during or
after VIT are shown in Table 4.Risk factors for recurring sting-induced anaphylaxis
during or after VIT
Of several putative risk factors or predictors for systemic
reactions to Hymenoptera field stings during or after
VIT, only one reached statistical significance: severe ana-
phylaxis following the pre-VIT index sting was clearly
related to future recurrence (P = 0.02). Tendencies to-
wards an increased risk of relapse in patients reporting
repetitive field stings after initiation of VIT (P = 0.07) or
patients receiving honey bee VIT compared to those re-
ceiving VespulaVIT (P = 0.50) did not reach statistical sig-
nificance. Patients with recurring Hymenoptera-venom
induced anaphylaxis tended to be older than patients
who tolerated field stings, but this was not statistically
significant (P = 0.40). No relation could be established
between recurrent anaphylaxis and the patient’s sex (P =
0.70), underlying atopy (P = 0.15) or asthma (P = 1.0),
life-time number of Hymenoptera stings (P = 0.46), the
decline of skin test reactivity (P = 0.45) or specific IgE
(P = 0.12) during VIT, the time interval from index stingTable 3 Clinical outcome of Hymenoptera field stings during
No reaction
I (mild
All stings 368 (92.9%) 13 (3.3%
Mono sensitized patients 156 (94.0%) 6 (3.6%
Double sensitized patients 212 (92.2%) 7 (3.0%
Stings during VIT 145 (96.7%) 3 (2.0%
Mono sensitized patients 67 (98.5%) 1 (1.5%
Double sensitized patients 78 (95.1%) 2 (2.4%
Stings after VIT discontinuation 223 (90.7%) 10 (4.1%
Mono sensitized patients 89 (90.8%) 5 (5.1%
Double sensitized patients 134 (90.5%) 5 (3.4%to initiation of VIT (P = 0.67), and the duration of VIT
(P = 0.56).Treatment efficacy in mono sensitized and double
sensitized patients
The overall relapse rates during and after VIT were 6.0%
in mono sensitized and 7.8% in double sensitized pa-
tients. Though there was a tendency towards an in-
creased risk of treatment failure, double sensitization
was not significantly related to relapsing sting-induced
anaphylaxis (P = 0.56, Table 5). This tendency, while not
reaching statistical relevance, was more pronounced in
the above defined subgroup of double sensitized patients
with equal reactivity to both venoms in diagnostic tests
(P = 0.15).Discussion
Standard dosed single venom-based immunotherapy over
3–5 years results in effective and long-lasting protection.
VIT constitutes an effective treatment to protect venom
allergic patients from sting-induced anaphylaxis [20].
Protection is highest during the maintenance phase and
tends to decrease after discontinuation of treatment,
resulting in overall relapse rates of approximately 10 to
15% [15,21-27]. Relapses following VIT-initiation tend to
be less severe than pre-VIT sting reactions [23,24,27],
but serious and even fatal Hymenoptera venom-induced
anaphylaxis does recur on rare occasions [22,28-30]. We
herein present the hitherto largest [22-26,31] single
centre observational cohort study investigating the long-
term outcome of VIT in a group of 635 Hymenoptera
venom-allergic patients who received standard dosed
treatment for 3 to 5 years between 1988 and 2008 (post-
VIT observation time was up to 17 years). In contrast to
other studies based on either challenge stings [27,32-35]
or field-sting-related observations [23-26,31], all patients
included received single VIT. Basic epidemiologicand after VIT
Anaphylactic reaction Total
) II (moderate) III (severe)
) 13 (3.3%) 2 (0.5%) 396 (100%)
) 4 (2.4%) 0 (0%) 166 (100%)
) 9 (3.9%) 2 (0.9%) 230 (100%)
) 2 (1.3%) 0 (0%) 150 (100%)
) 0 (0%) 0 (0%) 68 (100%)
) 2 (2.4%) 0 (0%) 82 (100%)
) 11 (4.5%) 2 (0.8%) 246 (100%)
) 4 (4.1%) 0 (0%) 98 (100%)
) 7 (4.7%) 2 (1.4%) 148 (100%)
Table 4 Characteristics of 28 patients suffering re-sting reactions during or after VIT
Patient
no.
Age1
(y)
Sex
(m/f)
BST
(μg/L)
Allergy testing VIT
duration
(y)
Post-VIT
observation
time (y)
No. of
stings4
Field
sting5
Severity of reactions (grade I-III)
Before VIT End of VIT
IgE2 bee IgE2 vesp ID3 bee ID3 vesp IgE2 bee IgE2 vesp ID3 bee ID3 vesp Before VIT During VIT After VIT
Patients receiving honey bee VIT
1 43 m n.d. 3 0 n.d. neg 3 0 0.1 neg 5 14 >5 bee II - I
2 20 m n.d. 6 1 0.001 1 2 0 0.1 neg 4 9 1 bee II LR I
3 39 f n.d. 3 1 0.01 neg 1 0 1 1 3 10 3 bee II LR I
4 53 f n.d. 2 0 0.001 1 2 0 0.01 0.1 3 14 1 bee II I -
5 53 m n.d. 6 4 0.001 0.01 3 0 0.001 0.1 5 8 1 vesp III - I
6 37 f n.d. 3 2 0.1 neg 2 1 0.1 neg 3 2 1 bee II - I
7 26 m n.d. 3 2 0.01 0.01 2 1 0.01 0.1 6 13 5 u III - II
8 11 m n.d. 3 4 0.001 0.1 3 3 0.1 0.01 5 2 4 u II II LR
9 28 f n.d. 4 2 0.001 0.01 2 0 0.1 0.1 5 12 2 bee III - II
Patients receiving Vespula VIT
10 18 f n.d. 0 3 neg 0.01 0 2 neg 0.01 5 12 2 vesp II LR I
11 50 f 7.63 0 2 neg 0.1 0 3 neg 1 5 2 2 vesp II LR II
12 39 f n.d. 0 2 neg 0.1 0 0 neg 0.01 3 8 6 vesp III - I
13 21 m 4,97 0 3 neg 0.001 0 2 neg 0.1 3 8 3 vesp II - II
14 47 f n.d. 0 2 neg 0.1 0 2 neg 1 5 4 1 vesp III - II
15 51 m n.d. 0 3 neg 0.001 0 0 neg 0.1 3 11 1 vesp III - I
16 48 f n.d. 0 2 neg 0.01 0 2 neg 0.1 5 4 1 u I - II
17 30 f n.d. 0 3 neg 0.1 0 0 neg 1 3 10 1 u II I -
18 56 f n.d. 0 5 neg 0.001 0 3 neg 0.1 5 7 1 vesp II - I
19 32 m n.d. 1 1 neg 0.1 0 0 1 0.1 4 13 3 vesp III LR II
20 54 m 6.69 3 2 1 0.1 2 2 neg 0.1 3 13 4 vesp III - III
21 53 m 110,0 3 3 0.1 0.01 0 1 1 1 3 11 3 u III - II
22 45 m n.d. 2 2 1 0.01 1 3 neg 0.1 5 4 3 vesp III II -
23 30 m n.d. 3 4 0.1 0.001 0 1 1 0.1 3 9 2 vesp I - III
24 55 f n.d. 2 2 0.01 0.01 0 0 1 0.1 4 8 2 vesp II I LR
25 40 m n.d. 2 3 0.01 0.001 n.d. n.d. n.d. n.d. 3 14 1 u III - I
26 37 m n.d. 2 3 0.01 0.01 2 2 0.1 1 3 9 3 u III - II
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Table 4 Characteristics of 28 patients suffering re-sting reactions during or after VIT (Continued)
27 39 f n.d. 2 5 1 0.001 1 2 1 0.1 6 9 2 vesp II - II
28 46 f n.d. 2 2 neg n.d. 2 2 1 0.1 3 13 3 vesp I - II
1Age at the time of VIT initiation, 2figures refer to semi-quantitative serological classes, 3figures refer to intradermal test endpoint concentrations (μg/mL), 4number of Hymenoptera stings after VIT initiation,
5Hymenoptera sting eliciting systemic reaction during or after VIT.
Abbreviations: bee honey bee, BST baseline serum tryptase, ID intradermal skin test, LR local reaction, n.d. not determined, neg negative, vesp, Vespula species, VIT venom immunotherapy, u unknown.
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Table 5 Impact of double sensitization on the outcome of
treatment
Mono sensitized
patients
Double sensitized
patients
Total cohort
All Subgroup*
Tolerated
field sting
156 (94.0%) 212 (92.2%) 73 (89.0%) 368 (92.9%)
Relapse 10 (6.0%) 18 (7.8%)1 9 (11.0%)2 28 (7.1%)
Sum 166 (100%) 230 (100%) 82 (100%) 396 (100%)
*Subgroup of double sensitized patients comprising individuals with equal
reactivity to both venoms in diagnostic tests.
1P = 0.56 (P-values result from statistical comparison of the risk of relapse in
mono sensitized and double sensitized patients).
2P = 0.15.
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VIT initiation, a slight male preponderance being more
pronounced in bee venom allergic patients [36], and a
21.3% rate of severe anaphylactic reactions following
pre-VIT index stings as well as the re-exposure rate of
62.4% (to any Hymenoptera sting after VIT-initiation)
and the overall relapse rate of 7.1% (that is 3.3% during
VIT and 9.3% after its discontinuation) are roughly in
line with those reported in earlier studies. Recurrent
anaphylaxis to Hymenoptera field stings was significantly
less severe than the pre-VIT index sting reaction (P =
0.004) which is again in accordance with previous
findings [24,27]. Grade III anaphylaxis recurred in only 2
individuals (Table 4, patients 20 and 23) following dis-
continuation of treatment (that is 0.5% of 396 patients
suffering re-stings). Number 23 was the only patient to
develop more severe anaphylaxis on the occasion of his
post-VIT field sting than before VIT. He got re-stung 6
years after discontinuation of treatment by more than 20
yellow jackets emerging from their nest. He did not use
his epinephrine injector and lost consciousness shortly
after developing generalized wheals.
We conclude that standard dosed single venom-based
immunotherapy over 3 to 5 years effectively and long-
lastingly protects the vast majority of Hymenoptera
venom allergic patients.
Treatment failure is related to a limited number of risk
factors
Of a number of potential risk factors for treatment failure,
only one reached statistical significance: severe anaphyl-
axis following the pre-VIT index sting was indicative of a
higher risk of recurrence (P = 0.02) which is in accordance
with the results of some previous studies [31,34], but was
not supported by others [24,26,27,32,37]. Case series and
epidemiological studies have clearly documented that
both, the severity of anaphylaxis to the index sting as well
as the risk of treatment failure, are related to an increase
of the baseline serum tryptase concentration [38-41].
Tryptase determination is nowadays an integrative part ofdiagnostic assessment in Hymenoptera venom allergic pa-
tients, but was not routinely available during the first dec-
ade of our study. As a result, we could not retrospectively
correlate the risk of treatment failure with baseline serum
tryptase concentrations in our study group (tryptase con-
centrations were available in 87 patients and exceeding
11.4 μg/L in 9 cases).
Other potential risk factors including the patient’s age
(P = 0.40), sex (P = 0.70), and preexisting atopy (P = 0.15),
as well as the decline of venom specific IgE (P = 0.12) and
skin test reactivity (P = 0.45) during VIT [24,25,27,31,42],
the duration of treatment [24,34] (P = 0.56), the culprit
insect [36] (P = 0.50), and repetitive exposure to Hymen-
optera field stings (P = 0.07) did not significantly correlate
with the outcome of VIT in our patient cohort. At least
two aspects, however, require critical reflection: i) Higher
relapse rates have been observed in honey bee venom al-
lergic patients by other authors [36]. We assume that our
inability to confirm a relation between the culprit stinging
insect and the outcome of VIT may be due to a statistical
type 2 error, meaning that the association would have
proved statistically significant in a cohort of patients
containing a higher proportion of honey bee venom aller-
gic individuals. ii) Though there was a tendency towards
an increased risk of relapse in individuals repeatedly suf-
fering Hymenoptera re-stings during and after VIT (P =
0.07), we could not statistically confirm repetitive stings as
a risk factor for treatment failure as reported in previous
studies [23,24]. Our findings, however, demonstrate that
tolerated field stings do not reliably predict long-term
protection as illustrated by patients 2, 3, 10, 11, and 19
(Table 4) who did not react to Hymenoptera stings during
VIT, but had anaphylactic reactions to re-stings following
discontinuation of treatment.
Most double sensitized patients are sufficiently protected
by single VIT
In Northern Europe, the vast majority of sting-related
anaphylactic reactions can be attributed to stings of
honey bees and Vespula species, Vespula stings being
the most common elicitor of venom-induced anaphyl-
axis in Germany. Our 55.3% rate of patients with double
sensitization to both venoms is in line with previous
studies reporting up to 59% of double positive sera [4],
depending on the system used for determination of
specific IgE [4,43]. Double positivity was more often
detected serologically than in intradermal tests (Table 2)
which is again in accordance with earlier findings [43].
As described previously [4,36], serological (P < 0.001)
and intradermal test reactivity (P = 0.001) as well as the
rate of double positivity (P < 0.001) were higher in bee
venom allergic patients.
Other than venom “cross-reactivity” due to partial se-
quence identity of protein allergens or cross-reactive
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allergen-based double sensitization, has been claimed to
necessitate VIT with both venoms [4,6,10,13]. A histor-
ical study published in 1992, however, suggested that
single venom-based immunotherapy effectively protects
most patients despite reactivity to more than one venom
[44], but did not statistically compare the outcome of VIT
in mono sensitized and double sensitized individuals.
In our allergy clinic, VIT is usually restricted to a sin-
gle venom (see Methods section and Figure 1 for the
process of decision making). During the study period,
only 14 patients received double VIT with honey bee
and Vespula venom and were therefore excluded from
evaluation (no relapses were reported in this small group
of patients). Our approach is based on the assumption
that sensitization to one or several Hymenoptera venoms
is a common finding in approximately 25% of an average
adult population [15,45], reflecting previous exposure to
Hymenoptera stings rather than clinical allergy. Though
asymptomatic sensitization is associated with an inter-
mediate risk of subsequent sting-related anaphylaxis
(which may reach 17% [15,46]), it is international
consensus that it is not an indication for VIT. In our
opinion this also applies to patients with a history of
anaphylactic sting reactions to one insect and a hitherto
asymptomatic sensitization to another – regardless of
its pattern or origin.
Our study specifically compared the efficacy of single
venom-based immunotherapy in mono sensitized and
double sensitized individuals. Relapse rates in both
groups (6.0% in mono sensitized and 7.8% in double sen-
sitized patients) were within or even below commonly
reported recurrence rates of 10 to 15%. Still, there was a
tendency (though not statistically significant) towards an
increased risk of field sting-related anaphylaxis in double
sensitized patients (P = 0.56). Of 28 patients suffering
re-sting reactions, 5 double sensitized individuals reacted
to an unidentified stinging insect (Table 4, patients 7, 8,
21, 25, and 26). One double sensitized patient (patient 5)
treated with honey bee VIT subsequently reacted to a
Vespula sting with a grade I reaction. This indicates a
remaining risk of a wrong or insufficient choice of venom
when using our above mentioned algorithm which is
based on the patient’s ability to provide correct sting-
related information or even visual identification of the cul-
prit stinging insect. Study data, however, demonstrate that
the future risk of anaphylactic reactions to either honey
bee or yellow jacket stings was well below the reported
17% rate [15,46] of anaphylactic sting reactions in healthy
adults with asymptomatic sensitization. While still not
reaching statistical significance, there was a tendency to-
wards an increased risk of relapsing sting-induced ana-
phylaxis in patients with equal reactivity to both venoms
in diagnostic tests (P = 0.15) when compared to the totalgroup of double sensitized patients (P = 0.56). We con-
clude that, in double sensitized individuals, the respective
degree of skin test and serological reactivity to both
venoms is indicative of their clinical relevance, meaning
that the culprit insect venom is likely to produce a stron-
ger response in diagnostic tests. It is self-evident that,
since there is no absolute correlation between specific IgE
levels or the degree of skin test reactivity with clinical re-
sponses to Hymenoptera stings [1], this conclusion is re-
stricted to the intra-individual comparison of test results
in double sensitized patients.
The overall low rate of relapsing anaphylaxis following
Hymenoptera field stings (7.1%) and the exceedingly low
rate of severe allergic reactions (0.5%) as observed in our
patient cohort confirm effective long-term protection of
mono sensitized and most double sensitized individuals
by single VIT. We conclude that time-consuming and
expensive double VIT should reasonably be reserved to
clinically double allergic patients with a history of sys-
temic reactions to both venoms. It may additionally be
considered in double sensitive patients with equal re-
activity to both venoms who have not reliably identified
the responsible stinging insect. In cases of doubt, add-
itional risk factors such as an elevated baseline serum
tryptase, a history of particularly severe anaphylactic re-
actions to pre-VIT index stings, or a high degree of
exposure to Hymenoptera stings should be taken into
account. The recent introduction of assays determining
specific IgE to recombinant major allergens rApi m1,
rVes v5 and rVes v1 [4-6] might further help to identify
double sensitized individuals at an increased risk of fu-
ture anaphylactic reactions to their “non-culprit” insect.
However, prospective clinical trials are needed to investi-
gate the positive predictive value of major allergen-based
IgE-sensitization.
Conclusions and clinical implications
i) In addition to a comprehensive history, the
respective degree of skin test and serological
reactivity should be taken into account to identify
the appropriate venom for immunotherapy in
double sensitized patients.
ii) 3 to 5 years of standard-dosed single venom-based
immunotherapy result in long-term effective
protection of the vast majority of Hymenoptera
venom allergic patients. Recurring anaphylaxis to
Hymenoptera field-stings during or after VIT is
generally less severe than the pre-VIT sting reaction.
iii) Treatment failure is related to a limited number of
risk factors including a history of severe pre-VIT
sting-induced anaphylaxis.
iv) No significant correlation between double
sensitization and relapsing venom-induced
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study group, indicating that VIT can be reasonably
confined to a single venom in most patients.
Abbreviation
VIT: (Venom immunotherapy).
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